Logo image of BLDR

BUILDERS FIRSTSOURCE INC (BLDR) Stock Fundamental Analysis

NYSE:BLDR - US12008R1077 - Common Stock

147.62 USD
-1.59 (-1.07%)
Last: 9/8/2025, 12:20:46 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to BLDR. BLDR was compared to 41 industry peers in the Building Products industry. BLDR has a medium profitability rating, but doesn't score so well on its financial health evaluation. BLDR is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

In the past year BLDR was profitable.
In the past year BLDR had a positive cash flow from operations.
Each year in the past 5 years BLDR has been profitable.
Each year in the past 5 years BLDR had a positive operating cash flow.
BLDR Yearly Net Income VS EBIT VS OCF VS FCFBLDR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B

1.2 Ratios

BLDR has a Return On Assets (6.60%) which is in line with its industry peers.
With a decent Return On Equity value of 18.10%, BLDR is doing good in the industry, outperforming 68.29% of the companies in the same industry.
The Return On Invested Capital of BLDR (9.90%) is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for BLDR is significantly above the industry average of 12.73%.
The last Return On Invested Capital (9.90%) for BLDR is well below the 3 year average (22.36%), which needs to be investigated, but indicates that BLDR had better years and this may not be a problem.
Industry RankSector Rank
ROA 6.6%
ROE 18.1%
ROIC 9.9%
ROA(3y)16.93%
ROA(5y)14.89%
ROE(3y)37.68%
ROE(5y)35.24%
ROIC(3y)22.36%
ROIC(5y)20.5%
BLDR Yearly ROA, ROE, ROICBLDR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

1.3 Margins

BLDR has a worse Profit Margin (4.74%) than 63.41% of its industry peers.
In the last couple of years the Profit Margin of BLDR has grown nicely.
BLDR has a Operating Margin of 7.70%. This is in the lower half of the industry: BLDR underperforms 65.85% of its industry peers.
BLDR's Operating Margin has improved in the last couple of years.
BLDR has a Gross Margin (31.58%) which is in line with its industry peers.
BLDR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.7%
PM (TTM) 4.74%
GM 31.58%
OM growth 3Y-6.99%
OM growth 5Y12.55%
PM growth 3Y-8.82%
PM growth 5Y16.6%
GM growth 3Y3.73%
GM growth 5Y3.86%
BLDR Yearly Profit, Operating, Gross MarginsBLDR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BLDR is creating value.
The number of shares outstanding for BLDR has been reduced compared to 1 year ago.
BLDR has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, BLDR has a worse debt to assets ratio.
BLDR Yearly Shares OutstandingBLDR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
BLDR Yearly Total Debt VS Total AssetsBLDR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

BLDR has a debt to FCF ratio of 3.93. This is a good value and a sign of high solvency as BLDR would need 3.93 years to pay back of all of its debts.
With a Debt to FCF ratio value of 3.93, BLDR perfoms like the industry average, outperforming 51.22% of the companies in the same industry.
A Debt/Equity ratio of 1.12 is on the high side and indicates that BLDR has dependencies on debt financing.
The Debt to Equity ratio of BLDR (1.12) is worse than 82.93% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF 3.93
Altman-Z N/A
ROIC/WACC0.97
WACC10.22%
BLDR Yearly LT Debt VS Equity VS FCFBLDR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 1.79 indicates that BLDR should not have too much problems paying its short term obligations.
BLDR has a Current ratio of 1.79. This is comparable to the rest of the industry: BLDR outperforms 41.46% of its industry peers.
BLDR has a Quick Ratio of 1.08. This is a normal value and indicates that BLDR is financially healthy and should not expect problems in meeting its short term obligations.
BLDR's Quick ratio of 1.08 is on the low side compared to the rest of the industry. BLDR is outperformed by 63.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.79
Quick Ratio 1.08
BLDR Yearly Current Assets VS Current LiabilitesBLDR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

3

3. Growth

3.1 Past

The earnings per share for BLDR have decreased strongly by -33.50% in the last year.
The Earnings Per Share has been growing by 40.71% on average over the past years. This is a very strong growth
The Revenue has decreased by -6.39% in the past year.
Measured over the past years, BLDR shows a quite strong growth in Revenue. The Revenue has been growing by 17.64% on average per year.
EPS 1Y (TTM)-33.5%
EPS 3Y4.76%
EPS 5Y40.71%
EPS Q2Q%-32%
Revenue 1Y (TTM)-6.39%
Revenue growth 3Y-6.23%
Revenue growth 5Y17.64%
Sales Q2Q%-4.99%

3.2 Future

Based on estimates for the next years, BLDR will show a decrease in Earnings Per Share. The EPS will decrease by -7.26% on average per year.
BLDR is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.01% yearly.
EPS Next Y-38.95%
EPS Next 2Y-20%
EPS Next 3Y-7.26%
EPS Next 5YN/A
Revenue Next Year-6.61%
Revenue Next 2Y-2.6%
Revenue Next 3Y0.01%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BLDR Yearly Revenue VS EstimatesBLDR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B 20B
BLDR Yearly EPS VS EstimatesBLDR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5 10 15

5

4. Valuation

4.1 Price/Earnings Ratio

BLDR is valuated correctly with a Price/Earnings ratio of 15.92.
75.61% of the companies in the same industry are more expensive than BLDR, based on the Price/Earnings ratio.
BLDR's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.02.
With a Price/Forward Earnings ratio of 20.01, BLDR is valued on the expensive side.
BLDR's Price/Forward Earnings is on the same level as the industry average.
When comparing the Price/Forward Earnings ratio of BLDR to the average of the S&P500 Index (22.66), we can say BLDR is valued inline with the index average.
Industry RankSector Rank
PE 15.92
Fwd PE 20.01
BLDR Price Earnings VS Forward Price EarningsBLDR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

BLDR's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. BLDR is cheaper than 68.29% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BLDR indicates a rather cheap valuation: BLDR is cheaper than 87.80% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 13.73
EV/EBITDA 11.63
BLDR Per share dataBLDR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

BLDR has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as BLDR's earnings are expected to decrease with -7.26% in the coming years.
PEG (NY)N/A
PEG (5Y)0.39
EPS Next 2Y-20%
EPS Next 3Y-7.26%

0

5. Dividend

5.1 Amount

BLDR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BUILDERS FIRSTSOURCE INC

NYSE:BLDR (9/8/2025, 12:20:46 PM)

147.62

-1.59 (-1.07%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners99.83%
Inst Owner Change-1.46%
Ins Owners2.49%
Ins Owner Change4.67%
Market Cap16.32B
Analysts77.04
Price Target142.66 (-3.36%)
Short Float %6.04%
Short Ratio2.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.42%
Min EPS beat(2)2.38%
Max EPS beat(2)12.47%
EPS beat(4)4
Avg EPS beat(4)6.07%
Min EPS beat(4)1.07%
Max EPS beat(4)12.47%
EPS beat(8)8
Avg EPS beat(8)12.44%
EPS beat(12)12
Avg EPS beat(12)27.52%
EPS beat(16)16
Avg EPS beat(16)42.11%
Revenue beat(2)0
Avg Revenue beat(2)-2.44%
Min Revenue beat(2)-2.96%
Max Revenue beat(2)-1.92%
Revenue beat(4)0
Avg Revenue beat(4)-7.3%
Min Revenue beat(4)-17.56%
Max Revenue beat(4)-1.92%
Revenue beat(8)1
Avg Revenue beat(8)-4.98%
Revenue beat(12)5
Avg Revenue beat(12)-1.63%
Revenue beat(16)9
Avg Revenue beat(16)2.64%
PT rev (1m)1.29%
PT rev (3m)-1.53%
EPS NQ rev (1m)-14.25%
EPS NQ rev (3m)-45%
EPS NY rev (1m)-14.61%
EPS NY rev (3m)-16.01%
Revenue NQ rev (1m)-3.05%
Revenue NQ rev (3m)-15.1%
Revenue NY rev (1m)-5.25%
Revenue NY rev (3m)-5.97%
Valuation
Industry RankSector Rank
PE 15.92
Fwd PE 20.01
P/S 1.02
P/FCF 13.73
P/OCF 10.35
P/B 3.91
P/tB N/A
EV/EBITDA 11.63
EPS(TTM)9.27
EY6.28%
EPS(NY)7.38
Fwd EY5%
FCF(TTM)10.75
FCFY7.28%
OCF(TTM)14.26
OCFY9.66%
SpS144.23
BVpS37.79
TBVpS-9.71
PEG (NY)N/A
PEG (5Y)0.39
Profitability
Industry RankSector Rank
ROA 6.6%
ROE 18.1%
ROCE 12.75%
ROIC 9.9%
ROICexc 9.99%
ROICexgc 22.22%
OM 7.7%
PM (TTM) 4.74%
GM 31.58%
FCFM 7.46%
ROA(3y)16.93%
ROA(5y)14.89%
ROE(3y)37.68%
ROE(5y)35.24%
ROIC(3y)22.36%
ROIC(5y)20.5%
ROICexc(3y)22.6%
ROICexc(5y)21.09%
ROICexgc(3y)52.47%
ROICexgc(5y)46.44%
ROCE(3y)28.8%
ROCE(5y)26.39%
ROICexcg growth 3Y-14.33%
ROICexcg growth 5Y9.79%
ROICexc growth 3Y-13.16%
ROICexc growth 5Y2.57%
OM growth 3Y-6.99%
OM growth 5Y12.55%
PM growth 3Y-8.82%
PM growth 5Y16.6%
GM growth 3Y3.73%
GM growth 5Y3.86%
F-Score4
Asset Turnover1.39
Health
Industry RankSector Rank
Debt/Equity 1.12
Debt/FCF 3.93
Debt/EBITDA 2.6
Cap/Depr 67.97%
Cap/Sales 2.43%
Interest Coverage 5.27
Cash Conversion 87.67%
Profit Quality 157.18%
Current Ratio 1.79
Quick Ratio 1.08
Altman-Z N/A
F-Score4
WACC10.22%
ROIC/WACC0.97
Cap/Depr(3y)73.83%
Cap/Depr(5y)71.85%
Cap/Sales(3y)2.2%
Cap/Sales(5y)1.81%
Profit Quality(3y)125.27%
Profit Quality(5y)102.16%
High Growth Momentum
Growth
EPS 1Y (TTM)-33.5%
EPS 3Y4.76%
EPS 5Y40.71%
EPS Q2Q%-32%
EPS Next Y-38.95%
EPS Next 2Y-20%
EPS Next 3Y-7.26%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.39%
Revenue growth 3Y-6.23%
Revenue growth 5Y17.64%
Sales Q2Q%-4.99%
Revenue Next Year-6.61%
Revenue Next 2Y-2.6%
Revenue Next 3Y0.01%
Revenue Next 5YN/A
EBIT growth 1Y-38.45%
EBIT growth 3Y-12.79%
EBIT growth 5Y32.41%
EBIT Next Year1.15%
EBIT Next 3Y6.94%
EBIT Next 5YN/A
FCF growth 1Y-61.23%
FCF growth 3Y-0.52%
FCF growth 5Y30.71%
OCF growth 1Y-55.18%
OCF growth 3Y2.41%
OCF growth 5Y30.02%